Clinical Trial Update: FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation trial of Lu-177-labeled PNT6555 (FRONTIER) for selected solid tumors assessing safety, tolerability and dosimetry; the study, sponsore…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Colorectal Cancer
• Esophageal Cancer
• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Pancreatic Ductal Adenocarcinoma
• Soft Tissue Sarcoma

Drugs mentioned

• Lu-177-PNT6555 (Lutetium-177 PNT6555)

Snippet

Sponsor: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Conditions: Pancreatic Ductal Adenocarcinoma, Colorectal Cancer | Phase 1 | Status: TERMINATED